5 ms·
https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html https://www.hhs.gov/about/news/2023/08/29/hhs-sel
by toomuchtodo 3y ago
https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-fi... ("HHS Selects the First Drugs for Medicare Drug Price Negotiation")
https://finance.yahoo.com/news/pharmaceutical-groups-lawsuit-over-medicare-030745838.html https://finance.yahoo.com/news/pharmaceutical-groups-lawsuit... ("Pharmaceutical group's lawsuit over Medicare drug price program dismissed")
Jon Stewart says it best (because of course he does): https://youtu.be/NpBPm0b9deQ?t=1153 https://youtu.be/NpBPm0b9deQ?t=1153
"The work of making this world resemble one that you would prefer to live in is a lunch pail [bleep] job, day in and day out, where thousands of committed, anonymous, smart, and dedicated people bang on closed doors and pick up those that are fallen and grind away on issues till they get a positive result."
You keep on grinding.
> The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare Part D, Medicare’s outpatient prescription drug benefit program, and Medicare Part B, which covers physician and outpatient services, including drugs administered by physicians and other providers. Under the new Medicare Drug Price Negotiation Program, the number of drugs subject to price negotiation will be limited to 10 Part D drugs for 2026, another 15 Part D drugs for 2027, another 15 Part D and Part B drugs for 2028, and another 20 Part D and Part B drugs for 2029 and later years. The number of drugs with negotiated prices available will accumulate over time.
https://www.kff.org/medicare/issue-brief/a-small-number-of-drugs-account-for-a-large-share-of-medicare-part-d-spending/ https://www.kff.org/medicare/issue-brief/a-small-number-of-d...
- mdorazio 3y agoThat's great, but private insurance and out of pocket accounts for almost 2x the annual drug spend that Medicare does [1]. So there's nothing stopping pharma companies from shifting the costs to maintain profits. In a way, this is a cost shifting exercise from Boomers to everyone else. Without a Medicare-for-all system, Congress could still easily stop this by capping pharma company profits but I haven't even seen an attempt to do so. [1] https://www.kff.org/medicare/issue-brief/how-does-prescription-drug-spending-and-use-compare-across-large-employer-plans-medicare-part-d-and-medicaid/ https://www.kff.org/medicare/issue-brief/how-does-prescripti...
- toomuchtodo 3y agoWell, hopefully, we can start replacing people in Congress who won’t vote for Medicare for all.
- twoodfin 3y agoIn case anyone is confused, the Part B “negotiation” is essentially price-fixing: If you reject the government’s final offer, your product is subject to a punitive federal excise (sales) tax no matter who you sell it to. That’s in no sense what we typically think of as a “negotiation”.
- twoodfin 3y agoSorry, Part D, the drug benefit.
- HDThoreaun 3y agoNever enter into a negotiation without leverage. This sounds exactly like the type of negotiation I engage in.
- twoodfin 3y agoYes, the federal government has a great deal of leverage over all individuals and businesses in its domain. But nobody would consider it a fair “negotiation” in any typical sense if the Feds offered you a choice of 60% of the market value to purchase your house or a 20% lien on your income for the next 20 years.
- toomuchtodo 3y ago> But nobody would consider it fair Life ain’t fair. Selling to Medicare is a privilege, not a right. You’re free to find other markets more favorable if preferred as a pharma company, that’s a choice. But they won’t, because other markets already turn the screws on them with their health systems (which they should, but that’s a philosophical argument depending on your belief system). Exploiters just mad the game changed.
- twoodfin 3y agoYes, in any negotiation, either party can walk away. But it’s a strange kind of “negotiation” where one party gets to take much of what they wanted in the first place when the other party walks away. When people hear “Medicare negotiating drug prices”, they think, “The feds using their purchasing power to negotiate lower rates.” But existing Part D purchasers were already giants like Aetna, with tons of leverage of their own. It wasn’t enough, so now we have selective price-fixing, dressed up as a “negotiation”. Maybe it’s a great policy, but if so, its supporters should stop lying about what it is and defend it on the merits.